These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26973127)

  • 41. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection.
    Zhang Z; Zhang JY; Wang LF; Wang FS
    J Gastroenterol Hepatol; 2012 Feb; 27(2):223-30. PubMed ID: 22004062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New insights into how HBV manipulates the innate immune response to establish acute and persistent infection.
    Revill P; Yuan Z
    Antivir Ther; 2013; 18(1):1-15. PubMed ID: 23363957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The immunopathogenesis of HBV infection.
    Koziel MJ
    Antivir Ther; 1998; 3(Suppl 3):13-24. PubMed ID: 10726052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.
    Mancini-Bourgine M; Fontaine H; Scott-Algara D; Pol S; Bréchot C; Michel ML
    Hepatology; 2004 Oct; 40(4):874-82. PubMed ID: 15382173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
    Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
    Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?
    Bertoletti A; Gehring AJ
    PLoS Pathog; 2013; 9(12):e1003784. PubMed ID: 24367255
    [No Abstract]   [Full Text] [Related]  

  • 47. Therapeutic vaccination in chronic hepatitis B virus carriers.
    Pol S; Michel ML
    Expert Rev Vaccines; 2006 Oct; 5(5):707-16. PubMed ID: 17181443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee.
    Pancholi P; Lee DH; Liu Q; Tackney C; Taylor P; Perkus M; Andrus L; Brotman B; Prince AM
    Hepatology; 2001 Feb; 33(2):448-54. PubMed ID: 11172348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B.
    Tan AT; Koh S; Goh W; Zhe HY; Gehring AJ; Lim SG; Bertoletti A
    J Hepatol; 2010 Mar; 52(3):330-9. PubMed ID: 20137825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.
    Yoon SK; Seo YB; Im SJ; Bae SH; Song MJ; You CR; Jang JW; Yang SH; Suh YS; Song JS; Kim BM; Kim CY; Jeong SH; Sung YC
    Liver Int; 2015 Mar; 35(3):805-15. PubMed ID: 24620920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New therapeutic vaccination strategies for the treatment of chronic hepatitis B.
    Liu J; Kosinska A; Lu M; Roggendorf M
    Virol Sin; 2014 Feb; 29(1):10-6. PubMed ID: 24452539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
    Lan P; Zhang C; Han Q; Zhang J; Tian Z
    Hepatology; 2013 Jul; 58(1):73-85. PubMed ID: 23447417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection.
    Zheng BJ; Zhou J; Qu D; Siu KL; Lam TW; Lo HY; Lee SS; Wen YM
    J Viral Hepat; 2004 May; 11(3):217-24. PubMed ID: 15117323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future considerations for dendritic cell immunotherapy against chronic viral infections.
    Atanley E; van Drunen Littel-van den Hurk S
    Expert Rev Clin Immunol; 2014 Jun; 10(6):801-13. PubMed ID: 24734867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel insights into immunotherapy for hepatitis B patients.
    Akbar SM; Al-Mahtab M; Jahan M; Yoshida O; Hiasa Y
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):267-76. PubMed ID: 26626120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
    Xu DZ; Wang XY; Shen XL; Gong GZ; Ren H; Guo LM; Sun AM; Xu M; Li LJ; Guo XH; Zhen Z; Wang HF; Gong HY; Xu C; Jiang N; Pan C; Gong ZJ; Zhang JM; Shang J; Xu J; Xie Q; Wu TF; Huang WX; Li YG; Xu J; Yuan ZH; Wang B; Zhao K; Wen YM;
    J Hepatol; 2013 Sep; 59(3):450-6. PubMed ID: 23669281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel approaches to new therapies for hepatitis B virus infection.
    Loomba R; Liang TJ
    Antivir Ther; 2006; 11(1):1-15. PubMed ID: 16518955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.